KORU Medical Systems Inc (KRMD)

[blue_skies]

the trends cited in Q1 will continnue and grow in Q2

Net sales rose 27% to $6.3 million in Q1 2020 from $5.0 million in Q1 2019, with growth in all product categories (pumps, needle sets, and tubing). We believe this growth was primarily driven by an increased utilization of our products by PIDD patients and ongoing expansion of Hizentra® into CIDP. Net sales for Q1 2020 also reflected higher clinical trial sales compared to Q1 2019

Second quarter revenue could reach $7.5 million.

Gross profit $4.4 million

Gross margins at least 61%

litigation expenses remain uneven and uncertain. At a certain point EMED will decide its cheaper and more practical to settle then continue losing in court and incurring additional legal fees.

Super26 will have an official launch late in the second quarter. This high flow option will bring additional visibility and business to KRMD

Concerns. No matter how diligent and proactive people and organizations are, potential Covid related health will remain